Chinese filament manufacturer eSUN has become a talked about filament, partially for the excellent prices the brand offers, but, preceding it was a filament developer, Shenzhen Esun Industrial Co., Ltd. was building materials additional generally. Founded in 2002, the company manufactured what they consider environmentally friendly materials for the industrial market, jumping into the 3D printing space in 2007 with their own brand of filaments. Now, the material manufacturer is eager to manufacture the big leap into the stock market, gaining admission of China’s NEEAQ (National Equities Exchange and Quotations) to the New OTC Market on February 23, 2016.
China’s New OTC Market, built in 2012, is intended to add a additional layer to the Chinese stock market where more compact businesses can trade without the same capital requirements as the Shanghai Stock Exchange. As is the case with OTC markets in the US, this in addition results in less scrutiny on the part of regulatory bodies, major to abuse and fraud. For instance, last year, the Chinese government caught signs that price manipulation was bringing place when one stock was seen trading as high as $16,145 per share. Since and so, the government has claimed to crackdown on OTC stocks abuse, but OTC markets are notorious for such fraud.
That does not intended that OTCs don’t have their fair share of good results stories. Organovo, for instance, began on the pink sheets in the US preceding building its way into the big leagues of the NYSE. The bioprinting company has since 3D printed kidney and liver tissue, partnered with big names like Johnson & Johnson and L’Oreal, and has actually spun out its own bioprinting materials firm. Hopefully for eSUN, the OTC can be a stepping stone to additional legitimacy and good results, particularly when the Chinese firm touts such a powerful message, “We believe that 21st is the era of biological economy, that can solve the oil crisis and environment pollution so that a genuine sustainable say may be reached.”